| abstract |
Disclosed are oxazolidin-2-one subsituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K. Examples of compounds of formula (I) are: (4S,5R)-3-[2’-Amino-2-((S)-3-methyl-morpholin-4-yl)-4’-trifluoromethyl-[4,5,]bipyrimidinyl-6-yl]-4-hydroxymethyl-5-methyl-oxazolidin-2-one, (4S,5R)-3-(2’-Amino-2-morpholin-4-yl-4-(trifluoromethyl)-[4,5’]bipyrimidinyl-6-yl)-4-hydroxymethyl-5-methyl-oxazolidin-2-one or (4S,5R)-3-(2’-Amino-2-morpholino-4’-(trifluoromethyl)-[4,5’-bipyrimidin]-6-yl)-5-(2-hydroxyethyl)- 4-methyloxazolidin-2-one. |